Tags : Spark Therapeutics

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 12 – 16, 2021)

ThermoFisher to Acquire PPD for ~$17.4B Published: Apr 16, 2021 | Tags: ThermoFisher, Acquire, PPD, ~$17.4B Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children Published: Apr 16, 2021 | Tags: Roche, Evrysdi (risdiplam), Receives, Health Canada, Approval, Spinal Muscular Atrophy, Adults, Children GSK Discontinues the P-II Trials of […]Read More

Insights+

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales […]Read More

M&A

 Roche to Acquire Spark Therapeutics for $4.3B

Shots: Roche acquires Spark Therapeutics, in all stock transaction for $114.50 /share in cash, making the total deal value $4.3B. Spark to receive premium of 122% based on its last day closing share price value i.e 22 February 2019 The focus of the acquisition is to expand Roche’s footprints in genetic disorders including blindness, hemophilia, […]Read More

Regulatory

Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec)

Shots: The approval is based on P-III trial, involving assesment of Luxturna vs control group patients, with inherited retinal disease (caused due to mutation in both copies of the RPE65 gene and sufficient viable retinal cells) Results: Vision improvement recorded @ 30 days following treatment, @1yr. MLMT (multi-luminance mobility test) (1.6); 65% patients successfully navigate […]Read More